Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
953
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Palmoplantar pustulosis with psoriatic arthritis ineffective to interleukin-17 inhibitors: two patients successfully treated with upadacitinib

Zeng-Yun-Ou Zhanga Department of Dermatology, West China Hospital, Sichuan University, Chengdu, ChinaView further author information
,
Wen-Yao Mia Department of Dermatology, West China Hospital, Sichuan University, Chengdu, ChinaView further author information
,
Yi-Yi Wanga Department of Dermatology, West China Hospital, Sichuan University, Chengdu, ChinaView further author information
&
Wei Lia Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China;b Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, ChinaCorrespondence[email protected]
View further author information
Article: 2280508 | Received 16 Oct 2023, Accepted 02 Nov 2023, Published online: 15 Nov 2023

References

  • Mrowietz U, van de Kerkhof PC. Management of palmoplantar pustulosis: do we need to change? Br J Dermatol. 2011;164(5):1–4. doi: 10.1111/j.1365-2133.2011.10233.x.
  • Brunasso AMG, Massone C. Recent advances in palmoplantar pustulosis. Fac Rev. 2021;10:62. doi: 10.12703/r/10-62.
  • Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020;21(3):355–370. doi: 10.1007/s40257-020-00503-5.
  • Ma M, Lu S, Hou X, et al. Novel JAK-1 inhibitor upadacitinib as a possible treatment for refractory SAPHO syndrome: a case report. Int J Rheum Dis. 2023;26(11):2335–2337. doi: 10.1111/1756-185X.14774.
  • Koga T, Sato T, Umeda M, et al. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: impact of this JAK inhibitor on T-cell differentiation. Clin Immunol. 2016;173:147–148. doi: 10.1016/j.clim.2016.10.003.
  • Mohr J, Rahbar Kooybaran N, Schon MP, et al. Response of palmoplantar pustulosis to upadacitinib. J Dtsch Dermatol Ges. 2023;21(3):280–282. doi: 10.1111/ddg.14969.
  • Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465–479. doi: 10.1038/s41584-022-00798-0.
  • Andersen YMF, Augustin M, Petersen J, et al. Characteristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis. Br J Dermatol. 2019;181(5):976–982. doi: 10.1111/bjd.17832.
  • Trattner H, Bluml S, Steiner I, et al. Quality of life and comorbidities in palmoplantar pustulosis - a cross-sectional study on 102 patients. J Eur Acad Dermatol Venereol. 2017;31(10):1681–1685. doi: 10.1111/jdv.14187.
  • Wang HM, Xu JM, Jin HZ. Characteristics and burdens of disease in patients from Beijing with generalized pustular psoriasis and palmoplantar pustulosis: multicenter retrospective cohort study using a regional database. Am J Clin Dermatol. 2023;24(6):991–1002. doi: 10.1007/s40257-023-00807-2.
  • Furer V, Kishimoto M, Tsuji S, et al. The diagnosis and treatment of adult patients with SAPHO syndrome: controversies revealed in a multidisciplinary international survey of physicians. Rheumatol Ther. 2020;7(4):883–891. doi: 10.1007/s40744-020-00235-2.
  • Hayem G. SAPHO syndrome. Rev Prat. 2004;54(15):1635–1636.
  • Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071. doi: 10.1002/art.39573.
  • McInnes IB, Anderson JK, Magrey M, et al. Trial of ­upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384(13):1227–1239. doi: 10.1056/NEJMoa2022516.
  • Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1):e002735. doi: 10.1136/rmdopen-2022-002735.
  • McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021;7(3):e001838. doi: 10.1136/rmdopen-2021-001838.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.